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To  combat  rising  incidence  of  serogroup  C  meningococcal  disease  in the  city  of Salvador,  Brazil,  the  Bahia
state  immunization  program  initiated  routine  childhood  immunization  with  meningococcal  C  conjugate
vaccine  (MenC)  in  February  2010,  followed  by mass  MenC  vaccination  of  city  residents  10–24  years  of
age  from  May  through  August  2010.  We  analyzed  trends  in  incidence  of  reported  cases  of  meningococcal
disease  and serogroup  distribution  among  meningococcal  isolates  identiﬁed  in hospital-based  surveil-
lance  in  Salvador  from  January  2000  to December  2011  and  estimated  vaccine  effectiveness  using  the
screening  method.  Annual  incidence  of  serogroup  C  meningococcal  disease  increased  from  0.1  cases  per
100,000  population  during  2000–2006  to 2.3  in  2009  and  4.1  in 2010,  before  falling  to 2.0 per  100,000
in  2011.  Estimated  coverage  of mass  vaccination  reached  80%,  67%  and  41%  among  10–14,  15–19 and
20–24  year  olds,  respectively.  Incidence  in 2011  was  signiﬁcantly  lower  than  average  rates  in 2008–2009
among  children  <5  years,  but  reductions  among  10–24  year  olds  were  not  signiﬁcant.  Among  10–24
year  olds,  a single  dose  of MenC  vaccine  was  100%  effective  (95%  conﬁdence  interval,  79–100%)  against
serogroup  C meningococcal  disease.  Low  coverage  in the population  targeted  for  mass  vaccination  may
have  limited  impact  on ongoing  transmission  of  serogroup  C meningococcal  disease  despite  high  vaccine
effectiveness.
.. Introduction
Epidemics of bacterial meningitis caused by Neisseria menin-
itidis, the meningococcus, were ﬁrst reported in Brazil in 1920
1]. Meningococcal epidemics since the 1970s have been associ-
ted with serogroups B and C (the last meningococcal A epidemic
n Brazil occurred in 1974) [2]. Following the predominance of
eningococcal serogroup B during the 1990s, serogroup C out-
reaks emerged throughout Brazil after 2000, gradually replacing
 as the most prevalent serogroup [3,4]. With the rising incidence
nd high associated case-fatality of meningococcal serogroup C
isease among young children and the availability of effective con-
ugate vaccines, several state and local governments purchased
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264-410X/© 2012 Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2012.06.044
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meningococcal serogroup C polysaccharide-protein conjugate vac-
cines (MenC) for routine infant immunization or outbreak control
in targeted age groups.
From  2007 to 2009, meningococcal serogroup C disease
increased substantially in the state of Bahia, with a ﬁve-fold
increase in the number of cases reported in the capital, Salvador.
In 2009, 194 cases of meningococcal disease (1.5 cases per 100,000
population) with 50 deaths (39% case-fatality) were reported to
the Bahia state health department, with 50% of the cases and 48%
of the deaths occurring in Salvador [5]. Meningococcal serogroup
C conjugate vaccine was introduced into the routine childhood
immunization schedule of the state of Bahia in February 2010,
with a two-dose primary immunization series (at 2 and 4 months)
followed by a booster dose in the second year of life. All chil-
dren younger than ﬁve years in the state of Bahia were eligible to
Open access under the Elsevier OA licensereceive at least one dose of MenC conjugate vaccine. During the ﬁrst
semester of 2010, unusually high numbers of meningococcal dis-
ease cases and deaths among persons older than 10 years occurred
in the city of Salvador, leading the state immunization program to
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onduct mass vaccination (a single dose) of city residents 10–24
ears of age from May  to August 2010. We  analyzed data from
eningitis surveillance and immunization programs to evaluate
he impact of vaccination on rates of meningococcal disease among
accinated age groups and those not targeted for vaccination.
.  Methods
.1. Surveillance for meningococcal disease
Reporting of suspected cases of meningitis is mandatory in
razil. Suspected cases of meningitis are reported by public and
rivate health facilities to municipal and state health depart-
ents using standardized case report forms from the national
otiﬁable Diseases Information System [Sistema de Informac¸ ão de
gravos de Notiﬁcac¸ ão (SINAN)]. Case report forms include patient
dentiﬁcation, age, gender, clinical signs and symptoms, sam-
les collected, diagnostic tests performed, antibiotic susceptibility
nd cerebrospinal ﬂuid (CSF) evaluation. Suspected meningococcal
isease includes the presence of fever, intense headache, pro-
use vomiting, neck stiffness, clinical signs of meningeal irritation
Kernig or Brudzinski), convulsions or petechial or purpural rash. In
nfants, clinical signs may  include irritability, persistant crying and
ulging fontanelle. Clinical presentation of meningococcal disease
s reported as meningitis, meningococcemia or meningitis with
eningococcemia based on physician diagnosis and laboratory
ndings. Conﬁrmed cases of meningococcal disease are deﬁned
y isolation of meningococci or positive antigen detection tests in
lood, CSF or normally sterile ﬂuid specimens from suspected cases.
or surveillance purposes, suspected cases may  also be classiﬁed as
onﬁrmed based on epidemiologic link to a laboratory-conﬁrmed
ase, or by identiﬁcation in Gram stain of gram-negative diplococcic
n a patient with suggestive symptoms and petechial or purpural
ash.
.2. Vaccination against meningococcal serogroup C disease
Brazil’s  national immunization program provides vaccines
ncluded in the recommended immunization schedule through the
niﬁed Health System [Sistema Unico de Saúde (SUS)], Brazil’s pub-
ic health system. State governments have autonomy to purchase
nd provide vaccines not included in the national immunization
rogram through the state immunization program. Bahia, with
 population of 13.6 million inhabitants, ranks fourth most pop-
lous among Brazil’s 27 states (including the Federal District)
nd had an annual estimated health budget of US$ 1.5 billion in
010 [6]. In February 2010, MenC-tetanus toxoid conjugate vaccine
MenC-TT, Neisvac-C®, Baxter Vaccines) was introduced into the
outine infant immunization schedule in the state of Bahia, Brazil,
ith ﬁnancing from the state government. After August, 2010,
nfants began receiving MenC-CRM197 conjugate vaccine (Novar-
is Vaccines), which was provided to all states for universal infant
mmunization through Brazil’s national immunization program.
he recommended schedule in all state immunization programs
as two doses in the ﬁrst year of life (either at 2 and 4 months or
 and 5 months of age), followed by one dose in the second year
f life (at 12 or 15 months). Catch-up vaccination was  provided for
hildren younger than two years of age in most states. In the state
f Bahia, catch-up vaccination included children younger than ﬁve
ears; one dose of MenC was recommended for those at least 12
onths of age in February 2010.
In addition, the state of Bahia purchased 1,876,863 doses
f MenC-TT in 2010 to control the epidemic of meningococcal
erogroup C disease in Salvador, the state capital and most populous
ity (estimated population 2,676,606, 21% of the state population). 30 (2012) 5541– 5546
MenC-TT  vaccine was used for mass vaccination of persons 10–19
years old in May  and June 2010. In August 2010, the state gov-
ernment received 447,983 doses of MenC-CRM197 from Brazil’s
national immunization program, which were used for mass vac-
cination of persons 20–24 years with a single dose. Children 5–9
years of age were not vaccinated.
MenC  vaccination was  offered at 52 vaccination posts through-
out the city. Vaccination was offered on Saturday and Sunday at the
beginning of each phase to minimize disruption of normal vaccina-
tion services. Social mobilization focused on the ﬁrst two days of
vaccination for each age group. Due to poor turnout among 20–24
year olds in 2010, vaccination was  offered for persons in this age
group during the second weekend in February 2011, and at large
universities the following week.
MenC doses administered by age group at each vaccination post
were reported to the immunization unit of the Salvador munici-
pal health department. For children younger than ﬁve years, MenC
doses administered were also registered in the information sys-
tem of the national immunization program according to whether
the dose was  the ﬁrst, second or third dose for a child. We  esti-
mated coverage with at least one dose of MenC vaccine among
children younger than ﬁve years using number of administered
doses registered as the ﬁrst dose in the information system of the
national immunization program (http://pni.datasus.gov,  accessed
May 24, 2012). We  estimated coverage with one dose of MenC vac-
cine among persons 10–24 years of age by dividing the number of
administered doses registered in summary sheets for MenC vacci-
nation campaigns by the estimated population of the target age
group in the city of Salvador. Population estimates for Salvador
from the 2010 census were obtained from the Brazilian Institute
of Geography and Statistics (IBGE), the Brazilian census bureau.
2.3.  Laboratory methods
N.  meningitidis isolated from patients with meningococcal dis-
ease were sent to the Central Public Health Laboratory for the
state of Bahia or the Molecular Biology Research Laboratory at the
Gonc¸ alo Moniz Research Center at the Oswaldo Cruz Foundation
in Salvador for characterization using serogroup-speciﬁc antisera
(Difco Laboratories, Detroit, MI,  USA), as described previously [7,8].
2.4. Statistical analysis
For  suspected meningitis cases, annual reporting rates for
2000–2011 were calculated by dividing the yearly number of sus-
pected meningitis cases among city residents reported to the state
health department by the estimated population of Salvador, Brazil.
Similarly, annual cumulative incidence of conﬁrmed meningococ-
cal serogroup C disease was calculated by dividing the number of
serogroup C cases in each age group by the corresponding pop-
ulation of Salvador. Rates were not adjusted for the proportion
of conﬁrmed meningococal disease of unknown serogroup. We
obtained population estimates for the city of Salvador from IBGE
and used 2000 census data and intercensus projections from the
census bureau to calculate rates for 2001 through 2007; for 2008
through 2011, we used the 2010 census estimate of the population.
For conﬁrmed meningococcal serogroup C disease, we calculated
age-speciﬁc relative risk (RR) and corresponding 95% conﬁdence
intervals contrasting incidence in 2011 to average pre-vaccine
incidence in 2008 and 2009. For 2011, we estimated vaccine effec-
tiveness (VE) of one dose of MenC vaccine among 10–24 year
olds using the screening method [9], as (1 – odds ratio [OR] of
vaccination among conﬁrmed meningococcal C cases to the pop-
ulation) ×100. Exact conﬁdence intervals for the OR were used to
estimate the lower 95% conﬁdence limit for vaccine effectiveness.
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. Results
Following seven years from 2000 to 2006 of declining report-
ng rates of suspected meningitis cases in the city of Salvador,
uspected meningitis rates increased substantially during 2007
hrough 2010, reaching 14.9 suspected meningitis cases per
00,000 population (Fig. 1). Conﬁrmed cases of meningococcal dis-
ase followed a similar pattern, falling from 74 conﬁrmed cases in
000 to a low of 15 in 2004 and then increasing rapidly from 2008
hrough 2010. From 2000 through 2006, meningococcal serogroup
as identiﬁed for isolates from 127 (45%) of 281 conﬁrmed cases
Fig. 1); 105 (83%) were serogroup B, 20 (16%) were serogroup C
nd 2 (1%) were other serogroups (A [n = 1] and W135 [n = 1]). From
007 through 2011, serogroup was determined for 335 (77%) of 437
eningococcal cases, and serogroup C replaced B as the most preva-
ent serogroup identiﬁed among conﬁrmed cases of meningococcal
isease (Fig. 1).
Based  on cases with known serogroup, cumulative incidence of
erogroup C meningococcal disease in the city of Salvador was  0.1
ases per 100,000 population per year from 2000 through 2006
Fig. 2) with 1 death (case-fatality, 5%). In 2007, 13 cases (0.45
ases/100,000 population) of serogroup C meningococcal disease
ere identiﬁed with 2 deaths (case-fatality, 15%); in 2008, 53 cases
1.8 cases/100,000 population) were identiﬁed with 4 deaths (8%)
nd in 2009, 69 cases (2.3 cases/100,000 population) with 10 deaths
14.5%). From 2007 to 2009, children younger than ﬁve years old
ccounted for 34 (25%) of 135 cases (incidence, 4.8 cases/100,000
hildren <5 per year; Fig. 3) and 4 (25%) of 16 deaths. Among 10–24
ear olds, there were 43 (32%) cases (5.2 cases/100,000 popula-
ion/year) and 3 deaths.
MenC  vaccine was introduced into the routine infant immu-
ization schedule in the city of Salvador in February 2010, with
 catch-up vaccination campaign for all children younger than 5
ears. In the ﬁrst month, 87,111 doses of MenC were administered
o children <5 years, reaching an estimated 44% coverage of the
arget population with at least one dose. By December 2010, an
stimated 92% of children younger than 5 years had received at
east one dose of MenC vaccine (Table 1).
In the ﬁrst six months of 2010, cases of meningococcal disease
ontinued to increase, with 93% of 63 cases among persons 10–24
ears of age. The state health department purchased an additional
enC vaccine and conducted mass vaccination in three phases
f persons 10–24 years of age. The ﬁrst phase, targeting 10–14
ear olds, began May  30; 160,554 (93%) of 172,624 MenC doses
dministered in this age group were applied in the ﬁrst weekend
f the campaign, reaching 75% of the target population. The second
hase, targeting those 15–19 years began June 12; 145,249 (96%) of
51,884 MenC doses administered in this age group were applied in
he ﬁrst weekend. The third phase, targeting 20–24 year olds, was
elayed until August 14; only 68,362 (67%) of 102,565 MenC doses
dministered in this age group were applied in the ﬁrst weekend.
t the end of the third phase, coverage with at least one dose of
enC had reached 80% among 10–14 year olds, 67% among 15–19
ear olds, and 40% among 20–24 year olds (Table 1). An additional
pportunity for 20–24 year olds was provided on February 12–13,
011, during which 28,647 MenC doses were administered in this
ge group.
To  evaluate the short-term effect of MenC vaccination, we
ontrasted age-speciﬁc incidence of meningococcal serogroup C
isease in 2011 to average incidence in 2008–2009 for targeted and
on-targeted age groups for MenC vaccination (Table 2). Among
hildren <5, incidence of serogroup C meningococcal disease fell
rom 7.5 cases per 100,000 per year during 2008–2009, to 4.0 in
010 and 2.0 per 100,000 in 2011, and was signiﬁcantly lower in
011 than during 2008–2009. Among 10–24 year olds, rates of
erogroup C disease were lower in 2011 than in 2010, but were 30 (2012) 5541– 5546 5543
not  signiﬁcantly lower than during 2008–2009 before mass vacci-
nation. Similarly, rates of serogroup C disease among children 5–9
years and adults 25 years and older who were not targeted for vac-
cination fell in 2011 but were not signiﬁcantly different from rates
during 2008 to 2009 (Table 2). During 2011, there were 55 con-
ﬁrmed cases of serogroup C meningococcal disease and 21 were
eligible for MenC vaccination; 4 case-patients were <5 years (2 < 1
year of age) and 17 were 10–24 years old, none had received MenC
vaccine. Based on the surveillance data, the effectiveness of a single
dose of MenC vaccine for prevention of serogroup C meningococcal
disease was  100% (95% conﬁdence interval, 79–100%).
4. Discussion
The introduction of MenC conjugate vaccine for infants in the
state of Bahia coincided with increasing incidence of meningococ-
cal serogroup C disease. The capital city of Salvador experienced
historic numbers of cases in older children and adults; the resulting
panic and demand for MenC vaccine quickly consumed available
supplies in the private sector, even at approximately US$ 100/dose.
In 2010, the Bahia state government invested US$ 30 million to
purchase MenC vaccines, including US$ 10 million to purchase
vaccine for the city of Salvador. MenC vaccine was offered at no
charge through the state immunization program; however, because
supplies were limited, vaccine was  offered only to persons in age
groups that experienced the highest disease incidence.
A  single dose of MenC vaccine after the ﬁrst year of life has
been shown to be highly effective for preventing both epidemic
and sporadic meningococcal disease [10–13]. The decision to offer
a single dose of MenC vaccine to children 1–4 years old and individ-
uals 10–24 years of age during the epidemic in Salvador was  based
on local epidemiology, resource constraints and experience with
MenC vaccines during meningococcal serogroup C epidemics in the
United Kingdom and other countries [4,11,12,14]. For infants, the
state health department prioritized available MenC vaccine to pro-
vide two  doses to prevent disease in the ﬁrst year of life, followed by
a booster in the second year of life. Administrative data suggested
good uptake of MenC vaccine among young children, although sur-
veys were not conducted to determine what proportion of children
completed recommended schedules. However, cases of meningo-
coccal serogroup C disease continued to occur among persons who
were eligible for vaccination, prompting an investigation of vac-
cine effectiveness. The results of this study identiﬁed no conﬁrmed
cases of meningococcal serogroup C disease in vaccinated or par-
tially vaccinated individuals through December 2011, consistent
with the high effectiveness of MenC conjugate vaccines observed in
the United Kingdom, Quebec, Spain and other settings [10,15–17].
Reasons for non-vaccination among case patients who were eligible
to receive MenC vaccine need to be investigated to inform future
vaccination strategies. Offering MenC vaccine over an extended
period of time might have helped achieve coverage targets; national
vaccination campaigns against inﬂuenza A(H1N1) and rubella in
Brazil achieved coverage targets among persons 20–29 years old by
providing multiple opportunities for vaccination over an extended
period [18,19].
The  increase in serogroup C meningococcal disease in Salvador,
Brazil, was characterized by elevated attack rates among ado-
lescents and young adults, as well as young children, with high
case-fatality, similar to patterns of epidemic meningococcal dis-
ease described in other settings [10,15,16]. Data from surveillance
for meningococcal disease, especially the availability of population-
based data to compare disease incidence by age group in the city
of Salvador [7], helped prioritize limited vaccine supplies. The
increase of meningococcal serogroup C disease in Salvador fol-
lowed a shift from predominance of serogroup B to serogroup C
5544 C.W.  Cardoso et al. / Vaccine 30 (2012) 5541– 5546
Fig. 1. Reporting rates of suspected meningitis cases and frequency of conﬁrmed meningococcal disease, according to serogroup of isolate, among residents of Salvador,
Brazil, 2000–2011.
Fig. 2. Reported incidence of meningococcal serogroup C disease among residents of the city of Salvador, Brazil, according to age category, 2000–2011.
Table  1
Number of MenC vaccine doses administered and estimated coverage of target population for routine and catch-up immunization of children and mass vaccination of persons
10–24  years of age in the city of Salvador, Brazil, 2010.
Age group, years Population Time period Number of MenC doses administered % of target population
<5 200,272 February–December 2010 184,600a 92.2
10–14  214,814 May–August 2010 172,624 80.4
15–19  225,379 June–August 2010 151,884 67.4
20–24  252,066 August 2010 102,565b 40.7
a Excludes doses registered as second or third doses.
b Excludes doses administered in February 2011.
C.W. Cardoso et al. / Vaccine 30 (2012) 5541– 5546 5545
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rst described in São Paulo in southeast Brazil [3], and spread-
ng throughout the country [4]. While the emergence of a virulent
erogroup C clone belonging to sequence type 103 complex may
ave contributed to epidemics in Brazil, steadily increasing inci-
ence of serogroup C meningococcal disease has been reported
rom the greater São Paulo metropolitan area since the late 1980s
3]. Further, meningococcal epidemics may  occur due to a variety
f factors; shifts of predominant serogroup have been identiﬁed
n other settings in Brazil without occurrence of epidemics [20].
or example, serogroup C meningococci belonging to the sequence
ype 103 complex have been identiﬁed in Salvador since 1996 (J.
eis, unpublished data). This clone has been associated with epi-
emics of meningococcal disease in Europe and other regions since
000 [3,21]. Natural cycles in meningococcal disease complicate
able 2
umulative incidence of conﬁrmed meningococcal serogroup C disease by time period an
Age group, years Population Beginning of
vaccination
2008–2009a 2
Cases Incidence per
100,000
C
<5 200,272 February-10 30 7.49 
5–9  161,475 N/A 13 4.03 1
10–14  214,814 May-10 20 4.66 1
15–19  225,379 June-10 10 2.22 1
20–24  252,066 August-10 10 1.98 1
25–29  297,758 N/A 7 1.18 1
30–39  476,921 N/A 12 1.26 1
40–49  392,966 N/A 15 1.91 
50+  445,694 N/A 5 0.56 
a Pre-vaccine comparison period deﬁned as January 2008–December 2009. Average an
ases  divided by twice the estimated population in 2010.
b Relative risk (RR) compares cumulative incidence in 2011 versus annual incidence duy of Salvador, Bahia, by age group of case patient, January 2008 through December
efforts  to document short-term impact of vaccination. Continuous
surveillance in Brazil for meningococcal disease and strain char-
acterization is needed to establish a baseline for vaccine impact
assessments.
This study is subject to a number of limitations. First, cases of
meningococcal disease may  have been missed or not reported to
the health department, isolates were not obtained for all episodes
of meningococcal disease for serogrouping and MenC vaccina-
tion may  not have been correctly recorded in case report forms.
Cases of serogroup C disease in vaccinated individuals may have
been missed, however, active case investigations did not identify
conﬁrmed meningococcal disease (regardless of serotype) in vac-
cinated or partially vaccinated individuals. Second, improvements
in surveillance and determination of serogroup for conﬁrmed cases
d age group, Salvador, Brazil, 2008–2011.
010 2011 Relative riskb 2011 vs.
2008–9 (95% CI)
ases  Incidence per
100,000
Cases  Incidence per
100,000
8 3.99 4 2.00 0.27 (0.09–0.75)
8 11.15 9 5.57 1.38 (0.59–3.23)
5 6.98 5 2.33 0.5 (0.18–1.33)
3 5.77 5 2.22 1 (0.34–2.92)
5 5.95 7 2.78 1.4 (0.53–3.67)
3 4.37 9 3.02 2.57 (0.95–6.90)
7 3.56 8 1.68 1.33 (0.54–3.26)
9 2.58 4 1.15 0.6 (0.19–1.8)
2 0.45 4 0.90 1.6 (0.42–5.9)
nual incidence during the pre-vaccine period was calculated as the total number of
ring pre-vaccine period (2008–2009).
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ontributed to higher detection rates of serogroup C disease. How-
ver, the replacement of serogroup B and emergence of a dominant
erogroup C clone suggested a true increase in serogroup C disease
uring the period. To control for improvements in surveillance,
e calculated relative risks over a short period with high detec-
ion rates. We  analyzed unadjusted rates, without redistribution
f cases of unknown serotype; therefore, rates are minimum esti-
ates of serogroup C disease incidence during the period. Third,
eningococcal disease incidence was not stable during the pre-
accine period and comparisons of age-speciﬁc relative risk of
isease were based on few cases. For calculation of relative risk,
e chose a pre-vaccine period when rates of serogroup C disease
ere increasing, potentially leading to an overestimation of vaccine
mpact. In addition, declining incidence of serogroup C disease in
011 among non-targeted groups suggested that factors other than
enC vaccination may  have contributed to lower rates. Differenti-
ting between vaccine impact and secular trends was  complicated
y natural variability in meningococcal disease [20,22]. Finally, we
id not account for MenC vaccination in the private sector. If indi-
iduals at lower risk of disease were more likely to be vaccinated,
accine effectiveness (speciﬁcally, the lower conﬁdence limit) may
ave been overestimated. However, persons of lower socioeco-
omic status may  have been more likely to receive MenC vaccine
han persons of higher status during the campaign, when MenC
accine was offered at public clinics.
The state of Bahia was the second Brazilian state to introduce
enC conjugate vaccine for infants; later the same year, MenC was
dded to recommended infant immunizations provided by Brazil’s
ational immunization program. Nationally, catch-up vaccination
ith a single dose of MenC was offered only for children <2 years
ld. To date, mass vaccination of older children and young adults
o control epidemic disease has only been conducted in the city
f Salvador. Surveillance for meningococcal disease needs to be
mproved. Ongoing surveillance will inform vaccination strategies
n other parts of the state and throughout Brazil, as well as to mon-
tor the long-term effectiveness of a single dose of MenC vaccine in
his population.
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